View graph of relations
  1. 2019
  2. Published
  3. Published
  4. 2018
  5. Published
  6. Published
  7. Published
  8. Published
  9. Published
  10. Published
  11. Published
    Smolders, J., Hupperts, R., & Damoiseaux, J. (2018). Chapter 8 - The Way Forward With Vitamin D in Multiple Sclerosis. In A. Minagar (Ed.), Neuroinflammation (Second Edition) (pp. 175-191). Academic Press.
  12. 2017
  13. Published
    Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H-P., Fox, E. J., Giovannoni, G., ... Coles, A. J. (2017). Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology, 89(11), 1107-1116.
  14. Published
    Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H-P., Havrdova, E., ... Arnold, D. L. (2017). Alemtuzumab CARE-MS II 5-year follow-up Efficacy and safety findings. Neurology, 89(11), 1117-1126.
  15. Published
    Lorscheider, J., Jokubaitis, V. G., Spelman, T., Izquierdo, G., Lugaresi, A., Havrdova, E., ... Kalincik, T. (2017). Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 89(10), 1050-1059.
  16. Published
    Kalincik, T., Manouchehrinia, A., Sobisek, L., Jokubaitis, V., Spelman, T., Horakova, D., ... MSBase Study Group (2017). Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 140(9), 2426-2443.
  17. Published
  18. Published
  19. Published
    de Jong, H. J. I., Kingwell, E., Shirani, A., Tervaert, J. W. C., Hupperts, R., Zhao, Y., ... British Columbia Multiple Sclerosi (2017). Evaluating the safety of beta-interferons in MS A series of nested case-control studies. Neurology, 88(24), 2310-2320.
  20. Published
  21. Published
    Iaffaldano, P., Simone, M., Lucisano, G., Ghezzi, A., Coniglio, G., Morra, V. B., ... Trojano, M. (2017). Prognostic Indicators in Pediatric Clinically Isolated Syndrome. Annals of Neurology, 81(5), 729-739.
  22. Published
  23. Published
    Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., ... Wolinsky, J. S. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 376(3), 209-220.
  24. Published
  25. Published
  26. 2016
  27. Published
    Claes, N., Fraussen, J., Vanheusden, M., Hellings, N., Stinissen, P., Van Wijmeersch, B., ... Somers, V. (2016). Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients. Journal of Immunology, 197(12), 4576-4583.
  28. Published
    Fraussen, J., Claes, N., Van Wijmeersch, B., van Horssen, J., Stinissen, P., Hupperts, R., & Somers, V. (2016). B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses. Clinical Immunology, 173, 124-132.
  29. Published
  30. Published
  31. Published
  32. Published
  33. Published
    Kister, I., Spelman, T., Alroughani, R., Lechner-Scott, J., Duquette, P., Grand'Maison, F., ... Butzkueven, H. (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology Neurosurgery and Psychiatry, 87(10), 1133-1137.
  34. Published
  35. Published
    Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., ... Kalincik, T. (2016). Defining secondary progressive multiple sclerosis. Brain, 139, 2395-2405.
  36. Published
  37. Published
  38. Published
  39. Published
    Jokubaitis, V. G., Spelman, T., Kalincik, T., Lorscheider, J., Havrdova, E., Horakova, D., ... Trojano, M. (2016). Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis. Annals of Neurology, 80(1), 89-100.
  40. Published
  41. Published
    Spelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., ... Butzkueven, H. (2016). Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 6(2), 102-115.
  42. Published
  43. Published
  44. Published
  45. Published
  46. 2015
  47. Published
    Kalincik, T., Cutter, G., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., ... Butzkueven, H. (2015). Defining reliable disability outcomes in multiple sclerosis. Brain, 138.
  48. Published
  49. Published
    Kalincik, T., Jokubaitis, V., Izquierdo, G., Duquette, P., Girard, M., Grammond, P., ... Butzkueven, H. (2015). Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 21(9), 1159-1171.
  50. Published
    Ribbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., ... Lechner-Scott, J. (2015). Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLOS ONE, 10(6), [e0122686].
  51. Published
    Bergamaschi, R., Montomoli, C., Mallucci, G., Lugaresi, A., Izquierdo, G., Grand'Maison, F., ... Trojano, M. (2015). BREMSO: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 22(6), 981-989.
  52. Published
    Jokubaitis, V. G., Spelman, T., Kalincik, T., Izquierdo, G., Grand'Maison, F., Duquette, P., ... Trojano, M. (2015). Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2(5), 479-491.
  53. Published
    Spelman, T., Kalincik, T., Zhang, A., Pellegrini, F., Wiendl, H., Kappos, L., ... Butzkueven, H. (2015). Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2(4), 373-387.
  54. Published
    He, A., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., Trojano, M., ... Kalincik, T. (2015). Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 72(4), 405-413.
  55. Published
Previous 1 2 3 Next